{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+gel&page=19",
    "query": {
      "intervention": "placebo gel",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 536,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+gel&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+gel&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:08:43.093Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02866695",
      "title": "Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "ingenol mebutate gel 0.015%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-10-06",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02866695"
    },
    {
      "nct_id": "NCT00986960",
      "title": "Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "repository corticotropin injection",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986960"
    },
    {
      "nct_id": "NCT03601247",
      "title": "Silicone Gel for Postsurgical Scars of the Eyelid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Scarring Due to Treatment"
      ],
      "interventions": [
        {
          "name": "silicone gel",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2018-08-01",
      "completion_date": "2024-01-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601247"
    },
    {
      "nct_id": "NCT02616250",
      "title": "MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.33% gel (Br)",
          "type": "DRUG"
        },
        {
          "name": "CD07805/47 (Br) placebo gel",
          "type": "OTHER"
        },
        {
          "name": "Ivermectin 1% cream (IVM)",
          "type": "DRUG"
        },
        {
          "name": "CD5024 (IVM) placebo cream",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2015-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 7,
      "location_summary": "Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616250"
    },
    {
      "nct_id": "NCT05886660",
      "title": "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Motion Sickness, Space",
        "Motion Sickness",
        "Sea Sickness"
      ],
      "interventions": [
        {
          "name": "DPI-386 Nasal Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repurposed Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-01-21",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2024-05-17",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05886660"
    },
    {
      "nct_id": "NCT01993225",
      "title": "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Androxal 12.5 mg/25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsules",
          "type": "DRUG"
        },
        {
          "name": "AndroGel 1.62%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2014-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Garden City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993225"
    },
    {
      "nct_id": "NCT03384784",
      "title": "Effect of Galantamine on Inflammation and Cognition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Associated Cognitive Motor Complex"
      ],
      "interventions": [
        {
          "name": "Galantamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-10-30",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384784"
    },
    {
      "nct_id": "NCT05428449",
      "title": "Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Androgenetic Alopecia",
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "GT20029 Gel",
          "type": "DRUG"
        },
        {
          "name": "GT20029 Gel Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suzhou Kintor Pharmaceutical Inc,",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 123,
      "start_date": "2022-02-10",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Salt Lake City, Utah",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05428449"
    },
    {
      "nct_id": "NCT01135069",
      "title": "Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne"
      ],
      "interventions": [
        {
          "name": "Tretinoin microsphere 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Brand Retin-A Micro tretinoin microsphere gel 0.1%",
          "type": "DRUG"
        },
        {
          "name": "placebo microsphere gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spear Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 480,
      "start_date": "2009-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-27",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 1,
      "location_summary": "Land O' Lakes, Florida",
      "locations": [
        {
          "city": "Land O' Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135069"
    },
    {
      "nct_id": "NCT00612742",
      "title": "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypoactive Sexual Desire Disorder"
      ],
      "interventions": [
        {
          "name": "testosterone gel",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioSante Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 3656,
      "start_date": "2008-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-15T14:08:43.093Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612742"
    }
  ]
}